Posted in | News | Nanobusiness

Amgen Acquires BioVex Group

Harris & Harris Group, Inc. (Nasdaq:TINY) notes that Amgen and BioVex Group, Inc., today announced the completion of the acquisition of BioVex Group, Inc.

The transaction provides Amgen with BioVex's lead product candidate, OncoVEXGM-CSF, a novel investigational oncolytic vaccine in Phase 3 clinical development that may represent a new approach to treating melanoma and head and neck cancer. The acquisition was initially announced on January 24, 2011.

Harris & Harris Group was an investor in privately held BioVex Group. Harris & Harris Group made its initial investment in BioVex Group in September 2007.

Harris & Harris Group is a publicly traded venture capital company that invests in nanotechnology and microsystems.



Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Harris and Harris Group. (2019, February 12). Amgen Acquires BioVex Group. AZoNano. Retrieved on May 25, 2024 from

  • MLA

    Harris and Harris Group. "Amgen Acquires BioVex Group". AZoNano. 25 May 2024. <>.

  • Chicago

    Harris and Harris Group. "Amgen Acquires BioVex Group". AZoNano. (accessed May 25, 2024).

  • Harvard

    Harris and Harris Group. 2019. Amgen Acquires BioVex Group. AZoNano, viewed 25 May 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.